BPC-157 (Tablets)

Overview

BPC-157 in tablet form represents an oral delivery approach for this widely studied gastric pentadecapeptide. Given that BPC-157 is derived from a protein found in gastric juice, it demonstrates notable stability in the acidic gastric environment, supporting the feasibility of oral administration research.

Mechanism of Action

The same mechanisms as injectable BPC-157 apply: VEGF upregulation, nitric oxide system modulation, FAK-paxillin pathway activation. The oral route adds gastrointestinal-specific effects, including direct contact with the gut mucosa, which may be advantageous for gut-targeted research applications like leaky gut, IBS, and inflammatory bowel conditions.

Research Context

Oral BPC-157 research explores its gastric acid stability, gastrointestinal absorption, and systemic bioavailability. Some researchers prefer the oral route specifically for gut healing applications, while others use it as a convenience alternative to injection.

Key Research Areas

Considerations for Researchers

Smaller vendor base compared to injectable BPC-157. Tablet dosing may differ from injectable protocols. The oral route provides direct gut exposure, which may be either advantageous or limiting depending on the research question.